

What is claimed is:

1. A therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein comprising a polypeptide, the amino acid sequence of which comprises the amino acid sequence shown in Figure 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371.
2. A therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein comprising a polypeptide, the amino acid sequence of which comprises the amino acid sequence shown in Figure 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371.
3. A therepeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein comprising a polypeptide, the amino acid sequence of which comprises the amino acid sequence shown in Figure 6 from about +1 to about +185.
4. A pharmaceutical composition which comprises an effective amount of the therapeutic agent of any of claims 1, 2 or 3 and a pharmaceutically acceptable carrier.
5. A method for treating a subject infected with a human immunodeficiency virus which comprises administering to the subject an effective amount of the pharmaceutical composition of claim 4.

6. An expression vector encoding the polypeptide of any of claims 1, 2, or 3.
- 5 7. A host cell comprising the expression vector of claim 6.
8. A bacterial host cell of claim 7.
9. An Escherichia coli host cell of claim 8.
- 10 10. A eucaryotic host cell of claim 7.
11. A mammalian host cell of claim 10.
- 15 12. A yeast host cell of claim 10.
13. A insect host cell of claim 7.
- 20 14. A method of producing the therapeutic agent of any of claims 1, 2, or 3 which comprises growing the host vector system of claim 6 under suitable conditions permitting production of the therapeutic agent and recovering the therapeutic agent so produced.

25

30

35